Complement activation and cardiac surgery: A novel target for improving outcomes

Anesthesia and Analgesia

Volumn 115, Issue 4, 2012, Pages 759-771

  Stahl, Gregory L ^a   Shernan, Stanton K ^a   Smith, Peter K ^b   Levy, Jerrold H ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A RECEPTOR INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR INHIBITOR; COMPLEMENT INHIBITOR; COMPSTATIN; HC 31496; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2 ANTIBODY; MANNOSE BINDING LECTIN ANTIBODY; NAFAMSTAT; PEXELIZUMAB; PROPERDIN ANTIBODY; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CORONARY ARTERY BYPASS GRAFT; HEART SURGERY; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SURGICAL PATIENT;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84866951198     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182652b7d     Document Type: Review

References (156)

1. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-4
2. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66
3. Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med 2003;31:S97-104
4. Hansen S, Selman L, Palaniyar N, Ziegler K, Brandt J, Kliem A, Jonasson M, Skjoedt MO, Nielsen O, Hartshorn K, Jorgensen TJD, Skjodt K, Holmskov U. Collectin 11 (CL-11, CL-K1) is a MASP-1/-3-associated plasma collectin with microbial-binding activity. J Immunol 2010;185:6095-104
5. McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006;211:759-66
6. Ji X, Azumi K, Sasaki M, Nonaka M. Ancient origin of the complement lectin pathway revealed by molecular cloning of mannan binding: Protein-associated serine protease from a urochordate, the Japanese ascidian, Halocynthia roretzi. Proc Natl Acad Sci USA 1997;94:6340-5
7. Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011;187:3751-8
8. Takahashi M, Ishida Y, Iwaki D, Kanno K, Suzuki T, Endo Y, Homma Y, Fujita T. Essential role of mannose-binding lectinassociated serine protease-1 in activation of the complement factor D. J Exp Med 2010;207:29-30
9. Inal, J. M., Laich, A., Miot, S. Complement C2 bypass mechanism involving the C3-convertase C4bBb. J Immunol 178[meetingabstracts], 53.16. 4-1-2007
10. Selander B, Martensson U, Weintraub A, Holmstrom E, Matsushita M, Thiel S, Jensenius JC, Truedsson L, Sjoholm AG. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 2006;116:1425-34
11. Kurizaki T, Abe M, Sanderson SD, Enke CA, Baranowska-Kortylewicz J. Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides. Mol Cancer Ther 2004;3:85-91
12. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J Immunol 1982;129:184-9
13. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984;160:1558-78
14. Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol 1992;178:7-30
15. Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a speciesselective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991;146:2345-51
16. Meri S. Protectin (CD59). Complement lysis inhibitor and prototype domain in a new protein superfamily. Immunologist 1994;2:149-55
17. Morgan BP. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects. Biochem J 1989;264:1-14
18. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: Mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981;1:165-209
19. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994;28:437-44
20. Morgan BP. Clinical complementology: Recent progress and future trends. Eur J Clin Invest 1994;24:219-28
21. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15:369-96
22. Ziccardi RJ. The first component of human complement (C1): Activation and control. Springer Semin Immunopathol 1983;6:213-30
23. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V. Human C4-binding protein: I. Isolation and characterization. J Exp Med 1978;148:207-22
24. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: Isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 1977;146:257-70
25. Jelezarova E, Vogt A, Lutz HU. Interaction of C3b(2)-IgG complexes with complement proteins properdin, factor B and factor H: Implications for amplification. Biochem J 2000;349:217-23
26. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503
27. Mulligan MS, Schmid E, Till GO, Hugli TE, Friedl HP, Roth RA, Ward PA. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol 1997;158:1857-61
28. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest 1989;83:637-46
29. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes: An in vitro model of immune vascular damage. J Clin Invest 1978;61:1161-7
30. Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activation by pore-forming structures: Pivotal role for interleukin-1alpha. Circulation 2000;101:1867-73
31. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996;149:953-61
32. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000;105:1363-71
33. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-67
34. Zhao H, Montalto MC, Pfeiffer KJ, Hao L, Stahl GL. Murine model of gastrointestinal ischemia associated with complementdependent injury. J Appl Physiol 2002;93:338-45
35. Wada K, Montalto MC, Stahl GL. Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 2001; 120:126-33
36. Jagels MA, Daffern PJ, Hugli TE. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: Epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 2000;46:209-22
37. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999;162:1127-36
38. Marks RM, Todd RFI, Ward PA. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 1989;339:314-7
39. Zhao H, Montalto MC, Pfeiffer KJ, Hao L, Stahl GL. Murine model of gastrointestinal ischemia associated with complement dependent injury. J Appl Physiol 2002;93:338-45
40. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappaB activation. Am J Pathol 1997;150:2019-31
41. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997;185:1619-27
42. Collard CD, Lekowski R, Jordan JE, Agah A, Stahl GL. Complement activation following oxidative stress. Mol Immunol 1999;36:941-8
43. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor-a-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995;155:1434-41
44. Rollins SA, Johnson KK, Li L, Birks C, Matis LA, Rother RP. Role of porcine P-selectin in complement-dependent adhesion of human leukocytes to porcine endothelial cells. Transplantation 2000;69:1659-67
45. Stahl GL, Reenstra WR, Frendl G. Complement mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ Res 1995;76:575-83
46. Zuraw BL, Christiansen SC. Pathophysiology of hereditary angioedema. Am J Rhinol Allergy 2011;25:373-8
47. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7
48. Gelfand JA, Boss GR, Conley CL, Reinhart R, Frank MM. Acquired C1 esterase inhibitor deficiency and angioedema: A review. Med (Baltimore) 1979;58:321-8
49. Wall RT, Frank M, Hahn M. A review of 25 patients with hereditary angioedema requiring surgery. Anesthesiology 1989;71:309-11
50. Chaney JD, Adair TM, Lell WA, McGiffin DC, Nielsen VG. Hemostatic analysis of a patient with hereditary angioedema undergoing coronary artery bypass grafting. Anesth Analg 2001;93:1480-2
51. Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, Vietsch H, Mannesse ML, Ziere B, Gobbi M, De Simoni MG. Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 2009;66:332-42
52. Mulligan MS, Yeh CG, Rudolph AR, Ward PA. Protective effects of soluble CR1 in complement-and neutrophilmediated tissue injury. J Immunol 1992;148:1479-85
53. Wurzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M, Gotze O. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991;8:328-40
54. Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien DM, Grijalva GA, Mueller JP, Nye SH, Squinto SP, Wilkins JA. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995;32:1183-95
55. Shastri KA, Logue GL, Stern MP, Rehman S, Raza S. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: Effect of C4A null allele. J Thorac Cardiovasc Surg 1997;114:482-8
56. Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol 2009;297:H1853-9
57. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-401
58. McGrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006;176:2950-7
59. Janatova J. Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers. ASAIO J 2000;46:S53-62
60. Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988;9:30-5
61. Rinder CS, Rinder HM, Smith BR, Fitch JCK, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72
62. Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Mollnes TE. Artificial surface-induced cytokine synthesis: Effect of heparin coating and complement inhibition. Ann Thorac Surg 2004;78:38-44
63. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86:845-57
64. Gu YJ, Mariani MA, Boonstra PW, Grandjean JG, van OW. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: The role of tissue injury by surgical incision. Chest 1999;116:892-8
65. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010;185:5628-36
66. Tan FT, Jackman H, Skidgel RA, Zsigmond EK. Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins. Anesthesiology 1989;70:267-75
67. Rent R, Ertel N, Eisenstein R, Gewurz H. Complement activation by interaction of polyanions and polycations: I. Heparin-protamine induced consumption of complement. J Immunol 1975;114:120-4
68. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PGM, van Hardevelt FWJ, de Beaumont EMFH, Wildevuur CRH, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery. Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-8
69. Shernan SK. Perioperative myocardial ischemia reperfusion injury. Anesthesiol Clin North America 2003;21:465-85
70. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-12
71. Royston D. Systemic inflammatory responses to surgery with cardiopulmonary bypass. Perfusion 1996;11:177-89
72. Stahl GL. Repefusion-injury during surgery: Role of the endothelium, oxidative stress and complement activation. New Surgery 2001;1:62-6
73. Rossen RD, Michael LH, Kagiyama A, Savage HE, Hanson G, Reisberg MA, Moake JN, Kim SH, Self D, Weakley S, Giannini E, Entman ML. Mechanism of complement activation after coronary artery occlusion: Evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res 1988;62:572-84
74. Rossen RD, Michael LH, Hawkins HK, Youker K, Dreyer WJ, Baughn RE, Entman ML. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res 1994;75:545-55
75. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982;45:587-95
76. Friedl HP, Till GO, Ryan US, Ward PA. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J 1989;3:2512-8
77. Kim SH, Carney DF, Hammer CH, Shin ML. Nucleated cell killing by complement: Effects of C5b-9 channel size and extracellular Ca2-on the lytic process. J Immunol 1987;138:1530-6
78. Berger H-J, Taratuska A, Smith TW, Halperin JA. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Am J Physiol Heart Circ Physiol 1993;265:H267-72
79. Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T, Okada H. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001;167:4651-60
80. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998-1001
81. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer ZV, Grove M, Klos A, Kohl J. Cutting edge: Guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: Evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000;165:5401-5
82. Chenoweth DE. Complement mediators of inflammation. In: Ross GD, ed. Immunobiology of the Complement System: An Introduction for Research and Clinical Medicine. Orlando: Academic Press, 1986:88-120
83. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC. C5a decreases regional coronary blood flow and myocardial function in pigs: Implications for a granulocyte mechanism. Circ Res 1988;63:483-91
84. Stahl GL, Amsterdam EA, Symons JD, Longhurst JC. Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. Circ Res 1990;66:1103-11
85. Stahl GL, Fletcher MP, Amsterdam EA, Longhurst JC. Role of granulocytes and C5a in myocardial response to zymosan-activated serum. Am J Physiol Heart Circ Physiol 1991;261:H29-37
86. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial ischemia: Role for CD18-dependent PMN localization and PMN-platelet interactions. Am J Physiol 1993;265:H1750-61
87. Stahl GL, Morse DS, Martin SL. Eicosanoid production from porcine neutrophils and platelets: Differential production with various agonists. Am J Physiol 1997;272:C1821-8
88. Braquet P, Paubert-Braquet M, Bourgain RH, Bussolino F, Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury: Consequences in shock, ischemia and graft rejection. J Lipid Mediators 1989;1:75-112
89. Ueda T, Rieu P, Brayer J, Arnaout MA. Identification of the complement iC3b binding site in the b2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci USA 1994;91:10680-4
90. Takizawa F, Tsuji S, Nagasawa S. Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. FEBS Lett 1996;397:269-72
91. Ohkuro M, Ogura-Masaki M, Kobayashi K, Sakai M, Takahashi K, Nagasawa S. Effect of iC3b binding to immune complexes upon the phagocytic response of human neutrophils: Synergistic functions between FcgammaR and CR3. FEBS Lett 1995;373:189-92
92. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-60
93. Collard CD, Agah A, Reenstra WR, Buras J, Stahl GL. Endothelial nuclear factor-kB translocation and vascular cell adhesion molecule-1 induction by complement: Inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler Thromb Vasc Biol 1999;19:2623-9
94. Cybulsky AV, Monge JC, Papillon J, McTavish AJ. Complement C5b-9 activates cytosolic phospholipase A2 in glomerular epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 1995;269:F739-49
95. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: Removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987;138:245-53
96. Busche MN, Walsh MC, McMullen ME, Guikema BJ, Stahl GL. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 2008;51:1544-51
97. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL. Mannosebinding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005;175:541-6
98. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: Role of cytokeratin 1. Am J Pathol 2001;159:1045-54
99. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannosebinding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001;104:1413-8
100. Montalto MC, Collard CD, Buras JA, Reenstra WR, McClaine R, Gies DR, Rother RP, Stahl GL. A keratin peptide inhibits mannose-binding lectin. J Immunol 2001;166:4148-53
101. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL. Complement activation following oxidative stress: Role of the lectin complement pathway. Am J Pathol 2000;156:1549-56
102. McBride WT, Armstrong MA, McBride SJ. Immunomodulation: An important concept in modern anaesthesia. Anaesthesia 1996;51:465-73
103. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992;36:201-20
104. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
105. Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S. Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol 2003;22:139-46
106. Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I. Increased surgical stress promotes tumor metastasis. Surgery 2003;133:547-55
107. Moudgil GC, Singal DP. Halothane and isoflurane enhance melanoma tumour metastasis in mice. Can J Anaesth 1997;44:90-4
108. Garred P, Madsen HO, Hofmann B, Svejgaard A. Increased frequency of homozygosity of abnormal mannan-bindingprotein alleles in patients with suspected immunodeficiency. Lancet 1995;346:941-3
109. Garred P, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003;188:1394-403
110. Best LG, Davidson M, North KE, MacCluer JW, Zhang Y, Lee ET, Howard BV, DeCroo S, Ferrell RE. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: The Strong Heart Study. Circulation 2004;109:471-5
111. Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P. Association of mannose-binding lectin deficiency with severe atherosclerosis. Lancet 1998;352:959-60
112. Rugonfalvi-Kiss S, Endresz V, Madsen HO, Burian K, Duba J, Prohaszka Z, Karadi I, Romics L, Gonczol E, Fust G, Garred P. Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation 2002;106:1071-6
113. Marenberg ME, Risch N, Berkman LF, Floderus B, De FU. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6
114. Mehrabian M, Lusis AJ. Genetic markers for studies of atherosclerosis and related risk factors. In: Lusis AJ, Rotter JI, Sparkes RS, eds. Molecular Genetics of Coronary Artery Disease: Candidate Genes and Processes in Atherosclerosis. Basel, Switzerland: Karger, 1992:363-418
115. Murata M, Kawano K, Matsubara Y, Ishikawa K, Watanabe K, Ikeda Y. Genetic polymorphisms and risk of coronary artery disease. Semin Thromb Hemost 1998;24:245-50
116. Fox AA, Shernan SK, Body SC. Predictive genomics of adverse events after cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8:297-315
117. Awdeh ZL, Alper CA. Inherited structural polymorphism of the fourth component of human complement. Proc Natl Acad Sci USA 1980;77:3575-80
118. Law SK, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 1984;3:1819-23
119. Zhang S, Li Q, Yao S. [Effect of complement 4 genetic polymorphism on complement activation during cardiopulmonary bypass in open heart surgery among children]. Zhonghua Yi Xue Za Zhi 2001;81:918-20
120. Zhang S, Wang S, Yao S. Evidence for development of capillary leak syndrome associated with cardiopulmonary bypass in pediatric patients with the homozygous C4A null phenotype. Anesthesiology 2004;100:1387-93
121. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260-7
122. Limnell V, Aittoniemi J, Vaarala O, Lehtimaki T, Laine S, Virtanen V, Palosuo T, Miettinen A. Association of mannanbinding lectin deficiency with venous bypass graft occlusions in patients with coronary heart disease. Cardiology 2002; 98:123-6
123. Takahashi K, Chang WC, Takahashi M, Pavlov V, Ishida Y, LA Bonte LR, Shi L, Fujita T, Stahl GL, Van Cott EM. Mannosebinding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011;216:95-102
124. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007;2:e623
125. La Bonte LR, Pavlov VI, Tan YS, Takahashi K, Takahashi M, Banda NK, Zou C, Fujita T, Stahl GL. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 2011;188:885-91
126. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, Farrar CA, Sacks S, Lee H, Zhang M, Iwaki D, Takahashi M, Fujita T, Tedford CE, Stover CM. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2011;108:7523-8
127. Walsh MC, Shaffer LA, Guikema BJ, Body SC, Shernan SK, Fox AA, Collard CD, Fung M, Taylor RP, Stahl GL. Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. J Immunol Meth 2007;323:147-59
128. Collard CD, Shernan SK, Fox AA, Bernig T, Chanock SJ, Vaughn WK, Takahashi K, Ezekowitz AB, Jarolim P, Body SC. The MBL2 "LYQA Secretor" haplotype is an independent predictor of postoperative myocardial infarction in Caucasians undergoing coronary artery bypass graft surgery. Circulation 2007;116:105-12
129. Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, Jarolim P, Body SC. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008;136:452-61
130. Reiner AP, Carlson CS, Rieder MJ, Siscovick DS, Liu K, Chandler WL, Green D, Schwartz SM, Nickerson DA. Coagulation factor VII gene haplotypes, obesity-related traits, and cardiovascular risk in young women. J Thromb Haemost 2007;5:42-9
131. Shernan SK, Collard CD. Role of the complement system in ischaemic heart disease: Potential for pharmacological intervention. BioDrugs 2001;15:595-607
132. Cedzynski M, Madalinski K, Gregorek H, Swierzko AS, Nowicka E, Obtulowicz K, Dzierzanowska-Fangrat K, Wojda U, Rabczenko D, Kawakami M. Possible disease-modifying factors: The mannan-binding lectin pathway and infections in hereditary angioedema of children and adults. Arch Immunol Ther Exp (Warsz) 2008;56:69-75
133. Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and-2. J Biol Chem 2001; 276:40880-7
134. Rossi V, Teillet F, Thielens NM, Bally I, Arlaud GJ. Functional characterization of complement proteases C1s/mannan-binding lectin-associated serine protease-2 (MASP-2) chimeras reveals the higher C4 recognition efficacy of the MASP-2 complement control protein modules. J Biol Chem 2005;280:41811-8
135. Davis AE 3rd. Biological effects of C1 inhibitor. Drug News Perspect 2004;17:439-46
136. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393-402
137. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, Becker P, Darius H, Rupprecht H-J, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997;95:701-8
138. Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G, Bierbach B, Petersen S, Bhakdi S, Darius H, Horstick M, Meyer J, Kempski O. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Dose-related beneficial versus detrimental effects. Circulation 2001;104:3125-31
139. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi P, Ruvolo G. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: A randomised double-blind study. Eur J Cardiothorac Surg 2007;32:325-32
140. Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998;24:635-8
141. Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004;77:942-9
142. Mathew JP, Shernan SK, White WD, Fitch JC, Chen JC, Bell L, Newman MF. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke 2004;35:2335-9
143. Verrier ED, Shernan SK, Taylor KM, Van de WF, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 2004;291:2319-27
144. Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, Todaro TG, Muhlbaier LH, Levy JH. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg 2011;142:89-98
145. Weisman HF, Bartow T, Leppo MK, Marsh HCJ Jr., Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:145-51
146. Rioux P. TP-10 (AVANT immunotherapeutics). Curr Opin Investig Drugs 2001;2:364-71
147. Lazar HL, Bao Y, Gaudiani J, Rivers S, Marsh H. Total complement inhibition: An effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 1999;100:1438-42
148. Chai PJ, Nassar R, Oakeley AE, Craig DM, Quick G Jr., Jaggers J, Sanders SP, Ungerleider RM, Anderson PA. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 2000;101:541-6
149. Li JS, Sanders SP, Perry AE, Stinnett SS, Jaggers J, Bokesch P, Reynolds L, Nassar R, Anderson PA. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J 2004;147:173-80
150. Lazar HL, Bokesch PM, van LF, Fitzgerald C, Emmett C, Marsh HC Jr., Ryan U. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004;110:II274-9
151. Van de Wouwer M, Collen D, Conway EM. Thrombomodulinprotein C-EPCR system: Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004;24:1374-83
152. Raivio P, Lassila R, Petaja J. Thrombin in myocardial ischemia-reperfusion during cardiac surgery. Ann Thorac Surg 2009;88:318-25
153. Zhang M, Hou YJ, Cavusoglu E, Lee DC, Steffensen R, Yang L, Bashari D, Villamil J, Moussa M, Fernaine G, Jensenius JC, Marmur JD, Ko W, Shevde K. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol 2011 Dec 15. [Epub ahead of print]
154. Krarup A, Gulla KC, Gal P, Hajela K, Sim RB. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 2008;1784:1294-300
155. Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010;31:1181-7
156. Pavlov VI, LA Bonte LR, Baldwin WM, Markiewski M, Lambris J, Stahl GL. Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol 2012;180:104-12